Nephroprotective effect of SGLT2 inhibitors in elderly patients with type 2 diabetes mellitus and hypertension: a real-world population-based cohort study
Open Access
- 13 November 2024
- journal article
- research article
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 136 (8) , 855-863
Abstract
Objectives: This study aimed to investigate the nephroprotective effect of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes mellitus (T2DM) and hypertension based on real-world clinical data. The study aimed to provide a theoretical basis for evidence-based pharmacological treatment of chronic kidney disease in this population. Methods: The 'Health Cloud' platform of the Shanghai Municipal Health Commission was employed to identify and screen elderly patients with T2DM and hypertension. The propensity score matching cohort was further constructed to estimate the effect of SGLT2i on the risk of rapid decline in renal function (triangle eGFR <=-5 ml/min/1.73 m(2) or triangle eGFR%<=-5%). Multiple sensitivity analyses were conducted to assess the robustness of the results. Results: After propensity score matching, no significant differences of covariates were identified between the SGLT2i and non-SGLT2i groups. The results of multivariate logistic models demonstrated a consistent and inverse correlation between SGLT2i use and the risk of rapid eGFR decline, whether defined as triangle eGFR <=-5 ml/min/1.73 m(2) (OR = 0.60, 95% CI:0.38-0.96) or triangle eGFR%<=-5%(OR = 0.57, 95% CI:0.37-0.89). In the stratification of renin-angiotensin system inhibitor (RASi) treatment, SGLT2i was associated with a lower risk of rapid eGFR decline in the RASi group (all ORs < 1, p < 0.05), with no interaction between SGLT2i and RASi (all P for interaction > 0.05) detected. Conclusions: SGLT2i significantly reduced the risk of rapid eGFR decline in elderly patients with T2DM and hypertension, but the synergistic effect with RASi remains unclear.Keywords
Funding Information
- National Key Research and Development Program of China (2022YFC3601504)
- Special Project of Clinical Research in Health Industry of Shanghai Municipal Health Commission (202140248)
- Leading Personnel Training Program of Pudong New Area Health System (PWRl2021-03)
This publication has 43 references indexed in Scilit:
- SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug?The Lancet Healthy Longevity, 2024
- Effects of SGLT2 inhibition via empagliflozin on cognitive and physical impairment in frail diabetic elders with chronic kidney diseasePharmacological Research, 2024
- Antidepressant drugs use and epilepsy risk: A nationwide nested case-control studyEpilepsy & Behavior, 2023
- KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney DiseaseKidney International, 2022
- Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 2022
- American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 UpdateEndocrine Practice, 2022
- Benefits of SGLT2 inhibitors combining with renin–angiotensin-system blockers on cardiovascular outcomes in chronic kidney disease patients: A systemic review and meta-analysisMedicina Clinica, 2022
- Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonistsDiabetes Research and Clinical Practice, 2022
- Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular DiseaseJAMA Network Open, 2022
- Benefits and harms of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2‐I) and renin–angiotensin–aldosterone system inhibitors (RAAS‐I) versus SGLT2‐Is alone in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trialsEndocrinology, Diabetes & Metabolism, 2021